Russell Richards

Non-Executive Chairman
life sciencess
Rodina Energy Group LLC
Ecuador

Biography

 entific Affairs with Pharmasset. From 2002 until its acquisition by Gilead Sciences (Nasdaq: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the deve

Research Intrest

 entific Affairs with Pharmasset. From 2002 until its acquisition by Gilead Sciences (Nasdaq: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the deve